MicroGEM, a provider of person-portable diagnostic devices and nucleic acid extraction products, and AiTmed, a provider of comprehensive telehealth solutions, have announced the MicroGEM Sal6830 SARS-CoV-2 Saliva Test is now available to AiTmed’s network of healthcare providers. The agreement provides access to AiTmed’s blockchain-encrypted telehealth platform, ensuring ready access to COVID-19 results provided through a full-service healthcare solution.
The agreement comes as the nation continues to average nearly 100,000 new cases and nearly 400 COVID-related deaths a day according to the Centers for Disease Control and Prevention (CDC).
“As we navigate the ‘new normal’ of living with COVID-19, Sal6830 is transforming the testing environment with fast point of care PCR results without the discomfort of nasal swabs,” says Jeff Chapman, president and CEO for MicroGEM. “Bundling Sal6830 [SARS-CoV-2 saliva test] with AiTmed’s telemedicine platform gives patients the ultimate user experience with ease of use, confidence in results, and the surety their medical records are secure and accessible – truly one-stop management of their healthcare needs.”
AiTmed has developed blockchain and Artificial Intelligence technology to give people the most secure and highest level of personal privacy to manage their healthcare needs. Blockchain is a digital ledger of records that is distributed and tracked across a peer-to-peer network. Blockchains, the foundation of cryptocurrency systems, guarantee the fidelity of data without the need for a third party.
“Our revolutionary blockchain technology is at the leading edge of telehealth services, offering the most secure and convenient way to manage complete health records, including COVID-19 results,” says Gary Chen, MD, CEO for AiTmed. “Together with MicroGEM’s first-of-its-kind saliva PCR test for point of care, we offer a powerful approach to assist with community infection control, all with no pain and no contact paperwork.”
AiTmed will leverage its extensive network of ambulatory care, surgery centers, and specialty clinics to provide practitioners with fast COVID-19 testing and a comprehensive healthcare management system. As MicroGEM expands the test menu offerings on the Sal6830 SARS-CoV-2 saliva test for pathogens of interest to public health and biomarkers important to wellness, those tests will also become available to AiTmed’s network.
The MicroGEM Sal6830 SARS-CoV-2 Saliva Test Point of Care PCR System is designed to capture intact virus, a key indicator of infectiousness. Sal6830’s non-invasive saliva sampling, no extra consumables or sample preparation, simple on-screen instructions, and fast on-the-spot PCR results give medical providers an invaluable tool to identify, isolate, and treat patients who are positive while proceeding with medical services for those who are negative. It protects healthcare workers, limiting their exposure to infective patients and providing a simple workflow for routine staff testing.
The MicroGEM Sal6830 SARS-CoV-2 Saliva Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories, including under a CLIA waiver. Find Sal6830 FDA EUA information here: https://microgembiocovid19.com/img/uploads/FDA%20language%20for%20website.pdf
